Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma

Table 3 Comparative analysis of immunological biomarker responses between the two groups, mean ± SD

	Experimental group (n = 45)	Control group (n = 44)	F value	P value
CD3+, %			43.869	< 0.001
Before treatment	54.09 ± 5.33	53.93 ± 5.21	0.011	0.918
3 months after treatment	69.18 ± 7.03	59.46 ± 6.72
CD4+, %			39.005	< 0.001
Before treatment	32.64 ± 3.84	33.03 ± 3.79	1.223	0.272
3 months after treatment	45.18 ± 4.91	39.06 ± 4.23
CD8+, %			84.859	< 0.001
Before treatment	30.55 ± 4.52	31.13 ± 4.78	0.158	0.692
3 months after treatment	21.76 ± 2.15	26.35 ± 2.52
CD4+/CD8+			103.782	< 0.001
Before treatment	1.10 ± 0.24	1.09 ± 0.22	0.643	0.425
3 months after treatment	2.10 ± 0.33	1.50 ± 0.22